Results 151 to 160 of about 66,449 (275)

SLPI/FBW7/c‐Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity

Cancer Science, EarlyView.
SLPI reduces the sensitivity of PDAC to gemcitabine by competing with FBW7 for binding to c‐Myc, thereby disrupting FBW7‐dependent ubiquitination and proteasomal degradation of c‐Myc, leading to increased c‐Myc stability and expression. SLPI knockdown could significantly increase gemcitabine sensitivity to gemcitabine‐induced direct cytotoxicity and NK
Haofei Chen, Xin Li, Weixiong Zhu, Yanxi Mu, Guoqing Zhang, Youheng Zhang, Yusheng Cheng, Wence Zhou   +7 more
wiley   +1 more source

Dynamic changes during the treatment of pancreatic cancer [PDF]

, 2018
This manuscript follows a single patient with pancreatic adenocarcinoma for a five year period, detailing the clinical record, pathology, the dynamic evolution of molecular and cellular alterations as well as the responses to treatments with ...
et al,, Wang-Gillam, Andrea, Wolff, Robert A   +2 more
core   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

Cancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka, Kyoko Kawasaki, Yoshiki Sumitomo, Masato Saito, Akari Yao, Munetoshi Ando   +5 more
wiley   +1 more source

2,3,7,8‑Tetrachlorodibenzo‑p‑dioxin suppresses the growth of human liver cancer HepG2 cells in vitro: Involvement of cell signaling factors. [PDF]

, 2018
The aryl hydrocarbon receptor (AHR) is transcriptionally active in the form of a heterodimer with the AHR nuclear translocator, which then binds to the xenobiotic responsive element.
Hankinson, Oliver, Yamaguchi, Masayoshi
core  

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source

Integrated multi-omics elucidates PRNP knockdown-mediated chemosensitization to gemcitabine in pancreatic ductal adenocarcinoma

Frontiers in Immunology
IntroductionPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an extremely poor prognosis. Gemcitabine (GEM), the standard first-line chemotherapeutic agent for PDAC, often fails due to the development of drug resistance ...
Bing Qi, Yuwei Wu, Ning Wang, Liumeng Duan, Yangbo Wei, Xuanrui Zhang, Jing Chen   +6 more
doaj   +1 more source

Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Peripheral blood single‐cell RNA‐seq from leukaemic CTCL defined three malignant T‐cell programmes: MTC CM, MTC Reg and MTC E/EM, each with distinct features and candidate vulnerabilities. For example, inferred immune circuits highlighted actionable IL‐10/JAK–TYK2–STAT3 signalling, KIR–MHC I inhibitory interactions and myeloid/B‐cell inflammatory and ...
Beth A. Childs, Eslam A. Elghonaimy, Praveen Ramakrishnan Geethakumari, Kiran A. Kumar, Joseph F. Merola, Heather W. Goff, Todd A. Aguilera   +6 more
wiley   +1 more source

Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT-2 pancreatic cancer mouse model. [PDF]

, 2019
学位記番号 ...
Higuchi, Tamami, ヒグチ, タマミ, 樋口, 珠美   +2 more
core  

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, Volume 158, Issue 12, Page 3091-3100, 15 June 2026.
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source